Transgene
Develops cancer immunotherapies using vaccines and oncolytic viruses.
TNG | PA
Overview
Corporate Details
- ISIN(s):
- FR0005175080
- LEI:
- 969500PDJW8N0FSGGK69
- Country:
- France
- Address:
- 400 BOULEVARD GONTHIER D'ANDERNACH, 67400 ILLKIRCH-GRAFFENSTADEN
- Website:
- https://www.transgene.fr/en/
Description
Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-04-24 08:00 |
Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai…
|
French | 277.8 KB | ||
| 2025-04-24 08:00 |
Availability of Preparatory Documents for the Combined General Meeting of May 1…
|
English | 262.6 KB | ||
| 2025-04-23 17:45 |
Transgene communiquera, dans une présentation orale rapide, de nouvelles donnée…
|
French | 414.8 KB | ||
| 2025-04-23 17:45 |
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Indiv…
|
English | 369.6 KB | ||
| 2025-04-10 20:15 |
Document d'Enregistrement Universel 2024
|
French | 5.3 MB | ||
| 2025-04-10 20:15 |
Mise à disposition du Document d’Enregistrement Universel (DEU) 2024 de Transge…
|
French | 140.9 KB | ||
| 2025-04-10 20:15 |
Availability of Transgene’s 2024 Universal Registration Document (URD)
|
English | 171.0 KB | ||
| 2025-04-10 15:38 |
Document d'enregistrement universel 2024
|
French | 5.3 MB | ||
| 2025-04-01 17:45 |
Transgene recrute une Directrice des opérations techniques (CTO) pour accélérer…
|
French | 377.5 KB | ||
| 2025-04-01 17:45 |
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
|
English | 390.3 KB | ||
| 2025-03-27 17:45 |
Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique…
|
French | 683.4 KB | ||
| 2025-03-27 17:45 |
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principl…
|
English | 532.2 KB | ||
| 2025-03-11 17:45 |
Transgene to Participate in Upcoming Investor Meetings
|
English | 260.4 KB | ||
| 2025-03-11 17:45 |
Transgene participera à de prochaines rencontres investisseurs
|
French | 259.7 KB | ||
| 2025-01-21 17:45 |
Transgene participera à la conférence investisseurs Biomed Forum
|
French | 274.2 KB |
Automate Your Workflow. Get a real-time feed of all Transgene filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Transgene
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Transgene via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-07-30 | N/A | Other | Other | 30,898,876 | 32,999,999.57 EUR |
| 2023-05-26 | N/A | Other | Buy | 29,325 | N/A |
Peer Companies
